Press Releases

Interim Results for the Six Months Ended 30 June 2017

Click here to download the full 2017 interim results statement – Strong NIOX® sales growth – – Duaklir® NDA filing on track following positive phase III results – – AstraZeneca US commercial collaboration progressing well...

View details

Circassia Announces European Launch of NIOX VERO® Nasal Mode for Screening of Primary Ciliary Dyskinesia

Click here to download full press release Oxford, UK – 12 September 2017: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the European launch...

View details

Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease

Click here to download the full press release – NDA submission planned H1 2018 by partner AstraZeneca – – Filing supported by positive results from ACHIEVE dose-ranging study – – Circassia has exclusive commercialisation rights...

View details

Notice of Interim Results

Oxford, UK – 24 August 2017: Circassia Pharmaceuticals plc (LSE: CIR) will announce its interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017. Following the results announcement, the company...

View details

Preliminary Results for the Year Ended 31 December 2016

Click here to download the full 2016 preliminary results statement – Transformational transaction with AstraZeneca for US commercial rights to two COPD products – – Leverages commercial infrastructure established as key growth platform – –...

View details

Circassia Announces Top-Line Results from House Dust Mite Allergy Field Study

Click here to download the full press release – Primary endpoint not achieved – – Treatment groups had greatly reduced Combined Score and symptoms – – Strong placebo effect mirrored previous cat allergy study –...

View details

Notice of Preliminary Results

Oxford, UK – 12 April 2017: Circassia Pharmaceuticals plc (LSE: CIR) will announce its preliminary results for the year ended 31 December 2016 on Tuesday 25 April 2017. A presentation for analysts will take place...

View details

Completion of the Transaction and admission to trading on the London Stock Exchange

Click here to download full announcement 12 April 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM...

View details

Proposed Collaboration and Securing of Certain U.S. Commercial Rights to Tudorza® and Duaklir® from AstraZeneca

Click here to download the full announcement 17 March 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR...

View details

Interim Results for the Six Months Ended 30 June 2016

Click here to download the full 2016 interim results statement – Strong NIOX® sales growth; respiratory pipeline progressing – – Unexpected phase III allergy results; Spring 2017 house dust mite results will inform allergy approach...

View details